PUDO INC.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTH PERIODS ENDED NOVEMBER 30, 2017

(EXPRESSED IN CANADIAN DOLLARS)

(UNAUDITED)

NOTICE TO READER

The accompanying unaudited condensed interim consolidated financial statements of PUDO Inc. have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars)

(Unaudited)

As at	N	lovember 30, 2017		February 28, 2017
Assets				
Current assets	_		_	
Cash	\$	682,627	\$	445,723
Restricted short-term investment Trade and other receivables (note 6)		25,000 124,626		25,000 117,736
Prepaid expenses and deposits		46,213		21,096
Trepaid expenses and deposits		70,213		21,090
Total current assets		878,466		609,555
Equipment (note 7)		27,043		61,530
Intangible assets (note 8)		270,596		339,956
Total assets	\$	1,176,105	\$	1,011,041
Liabilities				
Current liabilities				
Trade and other payables (notes 9 and 16)	\$	274,813	\$	406,612
Advances payable (note 10)		-		15,025
Loans and borrowings (note 11)		34,022		30,423
Total current liabilities		308,835		452,060
Loans and borrowings (note 11)		110,944		136,930
Total liabilities		419,779		588,990
Shareholders' equity				
Share capital (note 12)		5,102,619		3,971,811
Warrants (note 13)		507,173		136,137
Stock options (note 14)		225,402		333,427
Deficit		(5,078,868)		(4,019,324)
Shareholders' equity		756,326		422,051
Total liabilities and shareholders' equity	\$	1,176,105	\$	1,011,041

Nature of operations and going concern (note 1) Commitments and contingencies (note 17)

Approved by the Board of Directors:

<u>"Kurtis Arnold"</u> Director <u>"Richard Cooper"</u> Director

PUDO Inc.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars)

(Unaudited)

	Three Months Ended November 30,				s Ended er 30,		
		2017		2016		2017	2016
Revenue (note 4) Cost of sales (note 15)	\$	180,157 (49,175)	\$	282,882 (98,155)	\$	522,579 \$ (141,138)	661,706 (214,773)
Gross profit		130,982		184,727		381,441	446,933
Administrative expenses (note 15) Share-based payment (recovery) (note 14)		(496,609) 6,341		(390,333)		(1,355,321) (88,602)	(1,309,573) (35,250)
Operating loss Finance costs (note 11)		(359,286) (5,631)		(205,606) (6,703)		(1,062,482) (17,731)	(897,890) (20,707)
Net loss and comprehensive loss for the period	\$	(364,917)	\$	(212,309)	\$	(1,080,213)	\$ (918,597)
Loss per share - basic and diluted	\$	(0.02)	\$	(0.01)	\$	(0.06) \$	(0.06)
Weighted average number of shares outstanding - basic and diluted	1	18,975,634		16,320,514	1	7,627,450	16,319,150

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

PUDO Inc.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity
(Expressed in Canadian Dollars)
(Unaudited)

	# of commo shares		Share apital	٧	Varrants	Stock options	Deficit	-	Total
Balance, February 29, 2016	16,195,515	\$ 3,	366,283	\$	197,805 \$	277,508	\$(2,928,682)	\$	912,914
Issuance of common shares on									
acquisition of Kinek (note12(b)(i))	116,745		350,235		-	-	-		350,235
Broker warrants exercised (note 13)	8,254		-		-	-	-		-
Share-based payment (note 14)	-		-		-	35,250	(040 507)	10	35,250
Net loss for the nine month period ended November 30, 2016			-				(918,597)	(!	918,597)
Balance, November 30, 2016	16,320,514	\$ 3,	716,518	\$	197,805 \$	312,758	\$(3,847,279)	\$	379,802
Warrants expired (note 13)	-		_		(197,805)	_	197,805		_
Share-based payments (note 14)	-		-		-	31,004	-		31,004
Share-based payments forfeited (note 14)	-		-		-	(10,335)	10,335		, <u>-</u>
Issuance of common shares in private placement (note 12(b)(ii))	211,234		401,345		-	-	-		401,345
Valuation of broker warrants A and B issued in private									
placement (notes 12(b)(ii) and 13)	-	(1	136,137)		136,137	-	-		-
Transaction costs incurred for private placement (note 12(b)(ii))	-		(9,915)		-	-	-		(9,915)
Net loss for the three month period ended February 28, 2017	-		-		-	-	(380,185)	(3	380,185)
Balance, February 28, 2017	16,531,748	\$ 3,	971,811	\$	136,137 \$	333,427	\$(4,019,324)	\$	422,051
Stock options exercised (note 14(i))	150,000		51,771		-	(21,771)	-		30,000
Stock options exercised (note 14(ii))	1,200,000		414,187		-	(174,187)	-		240,000
Share-based payment (note 14)	-		-		-	88,602	-		88,602
Share-based payment forfeited (note 14)	-		-		-	(20,669)	20,669		-
Issuance of common shares in private placement (note 12(b)(iii))	869,160		869,160		-	-	-		869,160
Issuance of common shares in lieu of debt (note 12(b)(iii))	224,726		224,726		-	-	-		224,726
Issuance of stock options in lieu of debt (note 14(v))	-		-		-	20,000	-		20,000
Valuation of warrants issued in private placement (notes 12(b)(iii) at	nd 13) -	,	371,036)		371,036	-	-		(50,000)
Transaction costs incurred for private placement (note 12(b)(iii))	-		(58,000)		-	-	(4.000.040)	(4	(58,000)
Net loss for the nine month period ended November 30, 2017	<u>-</u>		-		<u>-</u>	-	(1,080,213)	(1	,130,213)
Balance, November 30, 2017	18,975,634	\$ 5,	102,619	\$	507,173 \$	225,402	\$ (5,078,868)	\$	756,326

PUDO Inc.

Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars)

(Unaudited)

	Nine Months ended November 30,				
		2017		2016	
Cash flows used in operating activities					
Net loss for the period	\$	(1,080,213)	\$	(918,597)	
Adjustments for:	•	(1,000,=10)	Ψ	(0.0,00.)	
Amortization (notes 7, 8 and 15)		129,847		127,864	
Share-based payment		88,602		35,250	
Accretion expense (note 11)		17,731		20,707	
Net change in non-cash working capital:					
Trade and other receivables		(6,890)		(32,689)	
Prepaid expenses and deposits		(25,117)		46,144	
Trade and other payables		47,906		86,474	
Cash flows used in operating activities		(828,134)		(634,847)	
Cash flows used in investing activities					
Purchase of equipment		(17,087)		(67,226)	
Purchase of intangible assets		(8,913)		(61,461)	
- Turoridae or interrigible dassets		(0,010)		(01,401)	
Cash flows used in investing activities		(26,000)		(128,687)	
Cash flows provided by (used in) financing activities					
Proceeds from exercise of options (note 14)		270,000		_	
Proceeds from issuance of common shares (note 12)		869,160		_	
Transaction costs incurred for private placement (note 12)		(8,000)		_	
Repayment of advances payable and borrowings		(40,122)		(26,748)	
Cash flows provided by (used in) financing activities		1,091,038		(26,748)	
Change in cash during the period		236,904		(790,282)	
Cash, beginning of period		445,723		891,301	
Cash, end of period	\$	682,627	\$	101,019	
Supplemental information:					
Issuance of common shares in lieu of debt (note 12)	\$	174,726	\$	-	
Options granted in settlement of debt (note 14)	•	20,000		-	
Shares issued in acquisition of Kinek (note 12)		-		350,235	

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

1. Nature of operations and going concern

PUDO Inc.'s (the "Company") principal activity is providing E-commerce shipment services through collaboration with specific online retailers for delivery of their products, and working with national and international courier companies to provide alternate drop-off and pickup options of packages.

These unaudited condensed interim consolidated financial statements have been prepared with the assumption that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. As at November 30, 2017, the Company had working capital of \$569,631, (February 28, 2017 - \$157,495), had not yet achieved profitable operations, had used cash in operating activities of \$828,134 for the nine month period ended November 30, 2017 (November 30, 2016 - \$634,847), and had a deficit of \$5,078,868 as at November 30, 2017 (February 28, 2017 - \$4,019,324). These conditions reflect material uncertainties which cast significant doubt about the Company's ability to continue as a going concern. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future. While the Company has been successful in raising the necessary funding to continue operations in the past, there is no assurance that it will be able to do so in the future. These unaudited condensed interim consolidated financial statements do not include the adjustments that would be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

2. Basis of preparation

(a) Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee ("IFRIC").

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting*. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by the IASB and interpretations issued by the IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of December 22, 2017, the date the Board of Directors approved the unaudited condensed interim consolidated financial statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual financial statements of the Company as at and for the year ended February 28, 2017 other than changes in accounting policies as discussed below.

(b) Basis of presentation

The unaudited condensed interim consolidated financial statements have been prepared on a historical cost basis, except for the restricted short-term investment, comprised of a guaranteed investment certificate, which is stated at its fair value. In addition, these unaudited condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

3. Significant accounting policies

(a) New standards not yet adopted and interpretations issued but not yet effective

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for the Company's accounting years beginning on or after March 1, 2018 or later years. Many are not applicable or do not have a significant impact to the Company and have been excluded. The following have not yet been adopted and are being evaluated to determine their impact on the Company.

IFRS 9 – Financial Instruments ("IFRS 9") was issued by the IASB in November 2009 with additions in October 2010 and August 2013 and will replace IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9, except that an entity choosing to measure a financial liability at fair value will present the portion of any change in its fair value due to changes in the entity's own credit risk in other comprehensive income, rather than within profit or loss. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. IFRS 9 is effective for annual years beginning on or after January 1, 2018.

IFRS 2 – Share-based Payments ("IFRS 2") was amended by the IASB in June 2016 to clarify the accounting for cash-settled share-based payment transactions that include a performance condition, the classification of share-based payment transactions with net settlement features and the accounting for modifications of share-based payment transactions from cash-settled to equity-settled. The amendments are effective for annual periods beginning on or after January 1, 2018.

IFRS 15 - Revenue From Contracts With Customers ("IFRS 15") proposes to replace IAS 18 - Revenue, IAS 11 - Construction Contracts, and some revenue-related interpretations. The standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized. IFRS 15 is effective for annual years beginning on or after January 1, 2018.

IFRS 16 – Leases ("IFRS 16") was amended in January 2016 which replaces IAS 17 - Leases and addresses the accounting of leases. IFRS 16 eliminates the classification as an operating lease and requires lessees to recognize a right-of-use asset and a lease liability in the statement of financial position for all leases with exemptions permitted for short-term leases and leases of low value assets. In addition IFRS 16 changes the definition of a lease, sets requirement on how to account for the asset and liability, including complexities such as non-lease elements, variable lease payments and options periods. IFRS 16 is effective for annual years beginning on or after January 1, 2019.

IFRIC 22 – Foreign Currency Transactions and Advance Consideration ("IFRIC 22") was issued in December 2016 and addresses foreign currency transactions or parts of transactions where there is consideration that is denominated in a foreign currency; a prepaid asset or deferred income liability is recognized in respect of that consideration, in advance of the recognition of the related asset, expense or income; and the prepaid asset or deferred income liability is non-monetary. The interpretation committee concluded that the date of the transaction, for purposes of determining the exchange rate, is the date of initial recognition of the non-monetary prepaid asset or deferred income liability. IFRIC 22 is effective for annual periods beginning on or after January 1, 2018.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

3. Significant accounting policies (continued)

(b) Changes in accounting standards

The Company has adopted the following amendments effective March 1, 2017.

IAS 7 – Statement of Cash Flows ("IAS 7") was amended in January 2016 to clarify that disclosures shall be provided that enable users of financial statements to evaluate changes in liabilities arising from financing activities. The amendments are effective for annual periods beginning on or after January 1, 2017.

IAS 12 – Income Taxes ("IAS 12") was amended in January 2016 to clarify that, among other things, unrealized losses on debt instruments measured at fair value and measured at cost for tax purposes give rise to a deductible temporary differences regardless of whether the debt instrument's holder expects to recover the carrying amount of the debt instrument by sale or by use; the carrying amount of an asset does not limit the estimation of probable future taxable profits; and estimates for future taxable profits exclude tax deductions resulting from the reversal of deductible temporary differences. The amendments are effective for annual periods beginning on or after January 1, 2017.

There was no material impact on the adoption of these standards on the unaudited condensed interim consolidated financial statements.

4. Financial risk management

(a) Fair values

The carrying amounts of trade and other receivables, cash, trade and other payables and advances payable approximate their fair values, given their short-term nature.

(b) Financial risk factors

The Company's activities expose it to a variety of financial risks, including credit risk, liquidity risk, market risk, and capital risk management. This note discloses information about the Company's exposure to each of the above risks, their objectives, policies and processes for measuring and managing risk and their management of capital.

The Board of Directors has the overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

(i) Credit risk

Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet commitments it has entered into with the Company. The financial assets that potentially expose the Company to credit risk consist principally of cash and receivables. The extent of the Company's exposure to credit risk approximate their carrying values are recorded in the Company's consolidated statement of financial position.

During the nine month period ended November 30, 2017, one customer represented approximately \$274,094 of revenue (November 30, 2016 - one customer represented approximately \$422,378 of revenue). Accounts receivable from one customer represents approximately \$46,192 of trade and other receivables as at November 30, 2017 (February 28, 2017 – \$67,364 from one customer). This one customer is comprised of three different

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

4. Financial risk management (continued)

businesses operated independently under common control. The maximum exposure to credit risk at the reporting date was:

	No	November 30, 2017		
Trade and other receivables Cash Restricted short-term investment	\$	124,626 682,627 25,000	\$	117,736 445,723 25,000
	\$	832,253	\$	588,459

(ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to finance its operations and to mitigate the effects of fluctuations in cash flows. See going concern discussion in note 1.

The following are the contractual maturities of financial liabilities:

	November 30, 2017		Feb	ruary 28, 2017
Trade and other payables Advances payable	\$	<pre><1 year 274,813 -</pre>	\$	< 1 year 406,612 15,025
	\$	274,813	\$	421,637
Loans and borrowings – 12 monthly instalments of \$4,458 < 1 year Loans and borrowings – 30 monthly instalments of \$4,458 > 1 year	\$ \$	53,496 133,740	\$ \$	53,496 173,862

In order to meet such cash commitments, the Company will be required to generate sufficient cash inflows from operating and financing activities.

(iii) Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. All of the Company's equipment and intangible assets are located in Canada. Revenue by geographic region is as follows:

	٦	Three Months Ended November 30,				Nine Months Ended November 30,			
		2017		2016	2017		2016		
Canada	\$	101,442	\$	204,753 \$	295,452	\$	442,517		
United States of America	\$	78,715	\$	78,129 \$	227,127	\$	219,189		
Total	\$	180,157	\$	282,882 \$	522,579	\$	661,706		

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

4. Financial risk management (continued)

Currency risk

Since the Company has a bank account denominated in US dollars, it is exposed to foreign currency risk due to fluctuations in the exchange rate. The Company purchases goods and services in Canadian dollars and US dollars. Since the Company reports its results in Canadian dollars, the functional currency of the Company, it is exposed to changes in the value of the US dollar relative to that of the Canadian dollar. The Company also entered into investment loan agreements which were denominated in US dollars which had exposed the Company to foreign currency risk due to fluctuations in the exchange rate. As at November 30, 2017, the Company had cash of US\$551,853 (\$702,785) (February 28, 2017 – US\$220,357 (\$288,690)) and accounts receivable of US\$42,340 (\$53,920) (February 28, 2017- US\$30,558 (\$40,034)) and accounts payable of US\$17,211 (\$21,919) (February 28, 2017 – US\$60,220 (\$79,503)).

Interest rate risk

The Company's exposure to risks of changes in market interest rates relates primarily to its cash and short-term investment balances. The Company regularly analyzes its interest rate exposure, giving consideration to potential renewals of existing positions, alternative financial positions and the mix of fixed and variable interest rates.

(iv) Capital risk management

The Company reviews and manages its capital position from time to time to maintain a balance between its liability and equity levels. The Company uses the capital contributed by investors to finance its working capital requirements.

The Board of Directors does not establish quantitative return on capital criteria for management but rather relies on the expertise of the Company's management to sustain future developments of the business. The Company defines capital as equity and borrowings.

The Company's capital management objectives, policies and processes have remained materially unchanged during the nine month period ended November 30, 2017 and year ended February 28, 2017.

(v) Sensitivity analysis

Based on management's knowledge and experience in the financial markets, the Company believes the following movements are reasonably possible over the year. Sensitivity to a plus or minus 1% change in the US–Canadian dollar foreign exchange rate, based on the current US dollar denominated balances as at November 30, 2017, would affect the net loss by approximately plus or minus \$7,000 during a twelve month period.

5. Critical accounting estimates and judgments

The Company makes estimates and judgments that affect the reported amounts of assets and liabilities within the next year. Estimates and judgments are regularly evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

In the determination of carrying values and impairment charges, management looks at the higher of recoverable amount or fair value less costs to sell in the case of assets and at objective evidence, significant or prolonged decline of fair value on financial assets indicating impairment. These determinations and their individual assumptions require that management make a decision based on the best available information at the end of each reporting year.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

5. Critical accounting estimates and judgments (continued)

Intangible assets and equipment

The useful life of intangible assets and equipment is determined by management at the time the software and equipment is acquired and brought into use and is regularly reviewed for appropriateness. For unique software products controlled by the Company, the estimated life is based on management's historical experience with similar products as well as anticipation of future events which may impact their life such as changes in technology.

In the determination of carrying values and impairment charges, management looks at the higher of recoverable amount or fair value less costs to sell and at objective evidence, significant or prolonged decline of fair value on assets indicating impairment. These determinations and their individual assumptions require that management make a decision based on the best available information at the end of each reporting year.

Income, value added, withholding and other taxes

The Company is subject to income, value added, withholding and other taxes. Judgment is required in determining the Company's provisions for taxes. The Company recognizes liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. The determination of the Company's income, value added, withholding and other tax liabilities requires interpretation of complex laws and regulations. The Company's interpretation of taxation law as applied to transactions and activities may not coincide with the interpretation of the tax authorities. All tax related filings are subject to government audit and potential reassessment subsequent to the financial statement reporting period. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the tax related accruals and deferred income tax provisions in the period in which such determination is made.

Share-based payments

The Company measures the cost of equity-settled transactions with employees and directors by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. Assumptions are made and judgment is used in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the stock price, expected dividend yield, future employee turnover rates and future employee stock option exercise behaviors and corporate performance. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates.

6. Trade and other receivables

	No	November 30, 2017		
Trade receivables HST receivable Other receivables	\$	100,259 15,579 8,788	\$	107,691 2,030 8,015
	\$	124,626	\$	117,736

There were no allowances for doubtful accounts as at November 30, 2017 and February 28, 2017.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

7. Equipment		
Cost Balance at February 29, 2016	\$	128,825
Additions	*	67,226
Disposals Release of February 28, 2047	\$	(46,053)
Balance at February 28, 2017 Additions	Φ	149,998 17,087
Balance at November 30, 2017	\$	167,085
Accumulated amortization		
Balance at February 29, 2016	\$	16,838
Amortization		105,122
Disposals Balance at February 28, 2017	\$	(33,492) 88,468
Amortization	Ψ	51,574
Balance at November 30, 2017	\$	140,042
Carrying amounts Balance at February 28, 2017	\$	61,530
Balance at November 30, 2017	\$	27,043
8. Intangible assets		
	Compu	iter Software
Cost Balance at February 29, 2016 Additions	Compu \$	25,000 589,098
Cost Balance at February 29, 2016		25,000
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017	\$	25,000 589,098 614,098
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017	\$	25,000 589,098 614,098 8,913
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions	\$ \$ \$	25,000 589,098 614,098 8,913 623,011
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017 Accumulated amortization and impairment Balance at February 29, 2016 Amortization and impairment	\$ \$ \$	25,000 589,098 614,098 8,913 623,011 11,042 263,100
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017 Accumulated amortization and impairment Balance at February 29, 2016	\$ \$ \$	25,000 589,098 614,098 8,913 623,011 11,042 263,100 274,142
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017 Accumulated amortization and impairment Balance at February 29, 2016 Amortization and impairment Balance at February 28, 2017	\$ \$ \$	25,000 589,098 614,098 8,913 623,011 11,042 263,100
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017 Accumulated amortization and impairment Balance at February 29, 2016 Amortization and impairment Balance at February 28, 2017 Amortization	\$ \$ \$ \$	25,000 589,098 614,098 8,913 623,011 11,042 263,100 274,142 78,273
Cost Balance at February 29, 2016 Additions Balance at February 28, 2017 Additions Balance at November 30, 2017 Accumulated amortization and impairment Balance at February 29, 2016 Amortization and impairment Balance at February 28, 2017 Amortization	\$ \$ \$ \$	25,000 589,098 614,098 8,913 623,011 11,042 263,100 274,142 78,273

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

9. Trade and other payables

	Nov	November 30, 2017		
Trade payables Other payables	\$	169,874 45,450	\$	286,519 31,418
Accrued liabilities		59,489		88,675
	\$	274,813	\$	406,612

10. Advances payable

At November 30, 2017, the Company had advances payable of \$nil (February 28, 2017 - \$15,025) owing to a shareholder of the Company. These advances were exchanged for 15,025 common shares on August 24, 2017 (see note 12).

11. Loans and borrowings

On March 3, 2016, the Company assumed borrowings from 640624 N.B. Ltd. (o/a Kinek) payable to Atlantic Canada Opportunities Agency. The loan is unsecured and non-interest bearing. Interest equal to 3% higher than the average Bank of Canada discount rate for the previous month is charged on any overdue balances. The present value of non-current borrowings was estimated using the effective interest rate method by discounting the future contractual cash flows at the estimated current market estimated interest rates for an equivalent instrument. The discount rate applied was 15%. During the three and nine month periods ended November 30, 2017, the Company recorded accretion expense of \$5,631 and \$17,731, respectively (November 30, 2016 - \$6,703 and \$20,707). The rate used in determining the appropriate present value of the borrowings was subject to significant management estimation.

		November 30, 2017	February 28, 2017
Loan payable (Atlantic Canada Opportunities Agency) 42 instalments repayable at \$4,458 per month Less: Discount future contractual cash flows	\$	187,236 42,270	227,358 60,005
Less: Current portion		144,966 34,022	167,353 30,423
	<u>\$</u>	110,944	136,930
Future repayments on the borrowings as at November 30, 2017	include the	e following:	
December 1, 2017 to February 28, 2018 March 1, 2018 to February 28, 2019 March 1, 2019 to February 29, 2020 March 1, 2020 to February 28, 2021 March 1, 2021 to June 22, 2021	\$	13,374 53,496 53,496 53,496 13,374	
Principal amount	\$	187,236	

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

12. Share capital

(a) Authorized

Unlimited number of common shares with no par value.

Unlimited number of preference shares. The preference shares are without par value, redeemable, voting, non-participating, and are convertible into common shares at the rate of one common share for five preference shares (none currently issued and outstanding).

(b) Issued

Common Shares	Number	Amount		
Balance of common shares, February 29, 2016	16,195,515	\$	3,366,283	
Exercise of broker warrants (note 13) Issuance of common shares in acquisition of Kinek (i)	8,254 116,745		- 350,235	
Issuance of common shares in private placement (ii) Transaction costs incurred for private placement (ii)	211,234		265,208 (9,915)	
Balance, February 28, 2017	16,531,748	\$	3,971,811	
Exercise of stock options (note 14)	1,350,000		465,958	
Issuance of common shares in private placement (iii)	869,160		869,160	
Issuance of common shares in lieu of debt (iii)	224,726		224,726	
Valuation of warrants issued in private placement (iii)			(371,036)	
Transaction costs incurred for private placement (iii)			(58,000)	
Balance, November 30, 2017	18,975,634	\$	5,102,619	

- (i) On March 3, 2016, the Company acquired certain assets and assumed certain liabilities from 640624 N.B. Ltd. In consideration for the business acquisition, the Company issued 116,745 common shares to Kinek with a value of \$3.00 per share.
- (ii) In February 2017, the Company closed a non-brokered private placement of 211,234 units at a price of \$1.90 per unit for total proceeds of \$401,345. Each unit is comprised of one common share and one-half of one common share purchase warrant A and one-half of one common share purchase warrant B. Each whole warrant A is exercisable into one common share of the Company at \$1.75 per share up to March 29, 2019. Each whole warrant B is exercisable into one common share of the Company at \$2.50 per share up to March 29, 2019. The warrants have an estimated grant date proportionate fair value of \$136,137 (comprised of \$72,908 related to Warrant A and \$63,229 related to Warrant B), using the Black-Scholes valuation model with the following assumptions: risk-free interest rate of 0.76%, expected life of 2.08 years, expected volatility of 120% based on the historical volatility of the Company's shares, and expected dividend yield of 0%. The Company incurred share issue costs of \$9,915 in connection with the private placement.
- (iii) In August 2017, the Company closed a non-brokered private placement of 508,580 units. Each unit is comprised of two common shares and two warrants. Each warrant entitles the holder to acquire one common share for \$1.00 per share up to August 24, 2018. The gross proceeds received as a result of the private placement is \$869,160.

With regard to this private placement the Company settled a total of \$224,726 in debt through the issuance to certain related party shareholders of 74,000 units (of the 508,580 units) at a deemed issue price of \$2.00 per unit, and 26,726 common shares at a deemed issue price of \$1.00 per common share.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

12. Share capital (continued)

The Company incurred share issuance costs of \$58,000 in connection with the private placement which includes a finder's fee of 25,000 units. The warrants have an estimated grant date proportionate fair value of \$371,036, using the Black-Scholes valuation model with the following assumptions: risk-free interest rate of 1.24%, expected life of 1.0 year, expected volatility of 128% based on the historical volatility of the Company's shares, and expected dividend yield of 0%.

13. Warrants

The following table reflects the continuity of warrants for the nine month period ended November 30, 2017 and the year ended February 28, 2017:

	Number of warrants	Exercise price		
Balance, February 29, 2016	242,737	\$	4.00	
Broker warrants exercised	(8,254)		0.63	
Warrants expired	(234,483)		4.00	
Warrants A issued in private placement (note 12(b)(ii))	105,617		1.75	
Warrants B issued in private placement (note 12(b)(ii))	105,617		2.50	
Balance, February 28, 2017	211,234	\$	2.12	
Warrants issued in private placement (note 12(b)(iii))	1,067,160		1.00	
Balance November 30, 2017	1,278,394	\$	1.19	

The following table reflects the warrants issued and outstanding as at November 30, 2017:

Expiry Date	Exercise price (\$)	Estimated proportionate fair value (\$)	Number of warrants outstanding
March 29, 2019	1.75	72.908	105,617
March 29, 2019	2.50	63,229	105,617
August 24, 2018	1.00	371,036	1,067,160
		507,173	1,278,394

On February 10, 2016, the Company issued 31,746 common shares, upon the exercise of 8,254 broker warrants.

On February 12, 2017, 234,483 warrants expired. The estimated grant date proportionate fair value of the warrants of \$197,805 was included in the deficit.

14. Stock options

The Company maintains an employee stock option plan under which the Board of Directors, or the compensation committee of the Board of Directors, may from time to time grant to employees, officers, directors or consultants of the Company, options to acquire common shares in such numbers, for such terms and at such exercise prices, as may be determined by the Board of Directors or the compensation committee of the Board of Directors.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

14. Stock options (continued)

The stock option plan provides that the maximum number of common shares in the capital of the Company that may be reserved for issuance for all purposes under the stock option plan shall not exceed 20% of the total issued and outstanding common shares. The following table reflects the continuity of stock options for the nine month period ended November 30, 2017 and the year ended February 28, 2017:

	Number of stock options	Exercise price		
Balance, February 29, 2016 Granted (i)	1,419,000 15,000	\$	0.30 3.00	
Options forfeited	(5,000)		3.00	
Balance, February 28, 2017	1,429,000	\$	0.30	
Options exercised (ii)	(1,350,000)		0.20	
Options forfeited (i)	(10,000)		3.00	
Granted (iii, iv and iv)	322,000		1.20	
Granted (vi)	2,690,000		1.30	
Balance, November 30, 2017	3,081,000	\$	1.31	

The following table reflects the actual stock options issued and outstanding as of November 30, 2017:

	Exercise price (\$)	Remaining contractual life (years)	Weighted average number of options outstanding	Options vested (exercisable)		stimated grant date air value
December 1, 2017	2.25	0.01	17,250	17,250	\$	27,700
March 1, 2018	2.25	0.25	17,250	17,250	•	28,800
June 1, 2018	2.25	0.50	17,250	17,250		29,700
September 1, 2018	2.25	0.75	17,250	17,250		30,600
August 14, 2019 (iii)	1.20	1.75	102,000	102,000		25,198
August 31, 2020 (iv)	1.20	2.75	200,000	200,000		63,404
August 31, 2020 (v)	1.20	2.75	20,000	20,000		20,000
October 26, 2022 (vi)	1.30	4.90	225,000	-		-
October 26, 2022 (vi)	1.30	4.90	2,465,000	-		
	1.31	2.32	3,081,000	391,000	\$	225,402

⁽i) On March 3, 2016, the Company granted 10,000 options to employees of the Company which were subsequently forfeited on July 11, 2017. The amount of \$20,669 was included in the deficit.

⁽ii) During the nine month period ended November 30, 2017, an officer of the Company exercised 1,200,000 options at \$0.20 per share and a director of the Company exercised 150,000 options at \$0.20 per share.

⁽iii) In July 2017, the Company granted an aggregate of 102,000 options to directors of the Company. The options are exercisable at a price of \$1.20 per common share and vest in 25% increments quarterly with the first 25% vesting on the date of grant. The stock options expire August 14, 2019. The grant date fair value of the stock options was estimated to be \$25,198 using the Black-Scholes valuation model with the following weighted

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

14. Stock options (continued)

average assumptions: expected dividend yield of 0%, expected volatility of 130%, risk-free interest rate of 1.24%, and expected life of 2.09 years. For the three and nine month periods ended November 30, 2017, \$25,198 and \$25,198, respectively (November 30, 2016 - \$nil and \$35,250) was recorded as share-based compensation in the unaudited condensed interim consolidated statement of loss.

- (iv) In July 2017, the Company granted an aggregate of 200,000 options to employees of the Company. The options are exercisable at a price of \$1.20 per common share. The stock options expire August 31, 2020. The grant date fair value of the stock options was estimated to be \$69,745 using the Black-Scholes valuation model with the following weighted average assumptions: expected dividend yield of 0%, expected volatility of 130%, risk-free interest rate of 1.32%, and expected life of 3.14 years. For the three and nine month periods ended November 30, 2017, \$63,404 and \$63,404, respectively (November 30, 2016 \$nil and \$nil) was recorded as share-based compensation in the unaudited condensed interim consolidated statement of loss.
- (v) In July 2017, the Company granted 20,000 options to an officer of the Company in lieu of a debt of \$20,000. The vesting date is October 1, 2017. The options are exercisable at a price of \$1.20 per common share. The stock options expire August 31, 2020.
- (vi) In October 2017, the Company granted 2,690,000 stock options to officers and directors of the Company. The options are exercisable at a price of \$1.30 per common share and expire on October 26, 2022. Of the total issued, 225,000 were issued to directors and vest in 33.33% increments yearly with the first 33.33% vesting on February 28, 2019. The balance of 2,465,000 options issued to officers vest in 25% increments yearly with the first 25% vesting on February 28, 2018. The grant date fair value of the stock options was estimated to be \$3,005,537 using the Black-Scholes valuation model with the following weighted average assumptions: expected dividend yield of 0%, expected volatility of 130%, risk-free interest rate of 1.76%, and expected life of 5 years. For the three and nine month periods ended November 30, 2017, \$nil and \$nil, respectively (November 30, 2016 \$nil and \$nil) was recorded as share-based compensation in the unaudited condensed interim consolidated statement of loss.

15. Expenses categorized by nature

Cost of sales

	Three Months Ended November 30,			Nine Months Ended November 30,		
		2017	2016	2017	2016	
External processing charges Computer and web access charges	\$	46,845 \$ 2,330	95,283 \$ 2,872	134,008 \$ 7,130	205,936 8,837	
	\$	49,175 \$	98,155 \$	141,138	214,773	

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

15. Expenses categorized by nature (continued)

Administrative expenses

	Three Months Ended November 30,			Nine Months Ended November 30,			
		2017		2016	2017		2016
Salaries and benefits	\$	203,670	\$	108,684	\$ 509,457	\$	372,993
General and administrative expenses		53,292		39,875	129,333		154,736
Advertising and promotion		(10,745)		2,631	6,804		17,262
Travel and business development		40,887		27,015	61,181		93,122
Consulting fees		121,814		77,214	260,615		202,957
Professional fees		26,453		40,763	107,278		138,556
Investor relations		2,300		26,270	33,046		101,068
Accounting and office		23,850		18,000	71,550		54,000
Agent and filing fees		8,111		6,260	35,678		40,435
Foreign exchange loss (gain)		(1,022)		(7)	10,532		6,580
Amortization expense		38,453		43,628	129,847		127,864
	\$	496,609	\$	390,333	\$ 1,355,321	\$	1,309,573

16. Related party transactions

(a) Related party balances and transactions:

During the three and nine month periods ended November 30, 2017 and November 30, 2016, the Company had the following transactions with shareholders and companies under common control and management and directors:

- incurred bookkeeping fees and office rent of \$23,850 and \$71,550, respectively, (three and nine months ended November 30, 2016 \$18,000 and \$54,000) to a company with a common director.
- incurred share-based payments (recovery) of (\$6,341) and \$88,602, respectively, (three and nine months ended November 30, 2016 \$nil and \$35,250) in relation to stock options granted to officers and directors of the Company (note 14).
- paid salary and consulting fees to officers, in the amount of \$162,000 and \$360,000, respectively, (three and nine months ended November 30, 2016 \$77,000 and \$222,000).

As at November 30, 2017, balances payable to the related parties and shareholders noted above amounted to \$23,052 (February 28, 2017 - \$135,806) and is included in trade and other payables. These balances are unsecured, non-interest bearing and due on demand.

See also notes 10, 12 and 14.

Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended November 30, 2017 and 2016 (Expressed in Canadian Dollars) (Unaudited)

16. Related party transactions (continued)

(b) Major shareholders:

None of the Company's major shareholders have different voting rights from other holders of the Company's common shares.

The Company is not currently aware of any arrangements, the operation of which may at a subsequent date result in a change in control of the Company.

17. Commitments and contingencies

The Company has entered into various agreements for services, which if terminated by the Company would require payments of approximately \$165,000. As the triggering events have not occurred, these amounts have not been accrued in the unaudited condensed interim consolidated financial statements as at November 30, 2017.